FOIA: OHRP Investigation – Brigham and Woment’s Hospital
FOIA: OHRP Investigation – Brigham and Women’s Hospital
Letter page one:
Letter page 2:
Letter page 3:
Similar Posts
Article
June 18, 2003. GlaxoSmithKline, manufacturer of Paroxetine (Seroxat, Paxil) issued a letter addressed to British Healthcare Professionals, disclosing that the drug was found be linked to serious undesirable effects in depressed children and adolescents under age 18. Below is an excerpt followed by the original letters: UNDESIRABLE EFFECTS Adverse events…
Selling Sickness: Pharma Industry Turning Us All Into Patients
Selling Sickness: Pharma Industry Turning Us All Into Patients Mon, 12 Sep 2005 Related Link: Selling Sickness Prologue Selling Sickness: How the World’s Pharmaceutical Companies Are Turning Us All Into Patients, by Ray Moynihan, an international health journalist, and Alan Cassels, a pharmaceutical policy researcher, is likely to become a…
FDA Warning Letter Re: Fatal Experiment: Hexamethonium Inhalation_Johns Hopkins
FDA Warning Letter Re: Fatal Experiment: Hexamethonium Inhalation_Johns Hopkins Tue, 22 Apr 2003 An FDA Warning Letter was sent to Dr. Alkis Togias of the Johns Hopkins University Asthma & Allergy Center (March 31, 2003). The letter lists specific federal safety requirements and their violation in the hexamethonium inhalation experiment…
Corporate Welfare Runs Amok – NYT Editorial
Corporate Welfare Runs Amok – NYT Editorial Sun, 30 Jan 2005 The administration has gone another step toward doing away with corporate taxes – by offering a “tax holiday” to America’s richest multinationals. The 35% corporate tax rate is being winnowed down to the “puny rate” of 5.25% for corporations…
NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market
NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market Wed, 2 Jun 2004 The New York Times saw fit to print a report about preliminary, unpublished findings of a study whose authors claim to have “found that Prozac helps teenagers overcome depression far…
Cong Hinchey Rebukes Daniel Troy, Chief Counsel FDA, for financial conflict of interest
Cong Hinchey Rebukes Daniel Troy, Chief Counsel FDA, for financial conflict of interest Tue, 13 Jul 2004 Daniel Troy, the FDA’s chief counsel, is under fire for his financial conflicts of interest and for perverting FDA’s mission “to ensure that the public is protected from unsafe food, drugs and other…